In this articleMRNAModerna said the Food and Drug Administration will need more time to complete its assessment of the biotech company's Covid-19 vaccine for children ages 12 to 17.The agency is looking specifically at the risk of myocarditis in kids, Moderna said in a statement Sunday, and the review may not be completed before January